Predictive Value of Initial PET-SUVmax in Patients with Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma

被引:72
作者
Rizk, Nabil P. [1 ]
Tang, Laura [1 ]
Adusumilli, Prasad S. [1 ]
Bains, Manjit S. [1 ]
Akhurst, Timothy J. [1 ]
Ilson, David [1 ]
Goodman, Karyn [1 ]
Rusch, Valerie W. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
关键词
Esophagus adenocarcinoma; PET scan; Preoperative chemoradiotherapy; POSITRON-EMISSION-TOMOGRAPHY; CELL LUNG-CANCER; FDG-PET; IN-VITRO; SURVIVAL; CARCINOMA; F-18-FDG; THERAPY; TRIAL; CHEMORADIOTHERAPY;
D O I
10.1097/JTO.0b013e3181a8cebf
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: We have previously shown that in early clinical stage esophageal adenocarcinoma, a positron emission tomography standardized uptake values (PET SUV(max)) of <4.5 is associated with earlier pathologic stage and predicts better survival. In this study, we analyze the impact of the pretreatment PET SUV(max), in patients with locally advanced esophageal adenocarcinoma who undergo preoperative chemoradiotherapy. Methods: We performed a retrospective analysis, selecting patients with adenocarcinoma of the esophagus who had a pretreatment PET scan and who received chemoradiotherapy before esophagectomy. Data recorded included demographics, PET SUV(max), treatment details, pathologic details, and survival data. Comparison of categorical variables was done by chi(2) analysis, continuous variables by I test, survival analysis by the Kaplan-Meier method, and comparisons of survival using the log-rank test. Results: Between January 1996 and September 2007, 189 patients were appropriate for this analysis. The initial PET SUV(max) was <4.5 in 28 patients and >= 4.5 in 161 patients. The two groups were similar with regards to demographics and treatment details. Patients in the low SUV group were less likely to show evidence of treatment response after chemoradiotherapy, including a higher likelihood of residual nodal disease and a lower likelihood of a pathologic complete response and estimated treatment response. However, both groups had similar survival. Conclusions: Although the initial PET SUV(max) does not predict survival in patients with locally advanced esophageal adenocarcinoma who receive preoperative chemoradiotherapy, patients with a high initial SUV(max) respond better to preoperative therapy. These results can be used to better select esophageal cancer patients for combined modality treatment.
引用
收藏
页码:875 / 879
页数:5
相关论文
共 21 条
[1]   Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC) -: A systematic review and meta-analysis (MA) by the European lung cancer working party for the IASLC lung cancer staging project [J].
Berghmans, Thierry ;
Dusart, Michele ;
Paesmans, Marianne ;
Hossein-Foucher, Claude ;
Buvat, Irene ;
Castaigne, Catherine ;
Scherpereel, Arnaud ;
Mascaux, Celine ;
Moreau, Michel ;
Roelandts, Martine ;
Alard, Stphane ;
Meert, Anne-Pascale ;
Patz, Edward F., Jr. ;
Lafitte, Jean-Jacques ;
Sculier, Jean-Paul .
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (01) :6-12
[2]  
Buck AK, 2003, J NUCL MED, V44, P1426
[3]   Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer [J].
Cerfolio, RJ ;
Bryant, AS ;
Winokur, TS ;
Ohja, B ;
Bartolucci, AA .
ANNALS OF THORACIC SURGERY, 2004, 78 (06) :1903-1909
[4]  
Cremerius U, 2001, NUKLEARMED-NUCL MED, V40, P23
[5]  
DIMTRAKOPOULOUS.A, 2003, RAD NUCL MED, V47, P8
[6]   Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection [J].
Downey, RJ ;
Akhurst, T ;
Gonen, M ;
Vincent, A ;
Bains, MS ;
Larson, S ;
Rusch, V .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3255-3260
[7]   Whole body 18FDG-PET and the response of esophageal cancer to induction therapy:: Results of a prospective trial [J].
Downey, RJ ;
Akhurst, T ;
Ilson, D ;
Ginsberg, R ;
Bains, MS ;
Gonen, M ;
Koong, H ;
Gollub, M ;
Minsky, BD ;
Zakowski, M ;
Turnbull, A ;
Larson, SM ;
Rusch, V .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (03) :428-432
[8]  
Higashi K, 2002, J NUCL MED, V43, P39
[9]  
Kalff V, 2006, J NUCL MED, V47, P14
[10]   High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy [J].
Lee, Kyung-Hun ;
Lee, Se-Hoon ;
Kim, Dong-Wan ;
Kang, Won Jun ;
Chung, June-Key ;
Im, Seock-Ah ;
Kim, Tae-You ;
Kim, Young Whan ;
Bang, Yung-Jue ;
Heo, Dae Seog .
CLINICAL CANCER RESEARCH, 2006, 12 (14) :4232-4236